Analysed KIORA PHARMACEUTICALS INC (KPRX:NASDAQ) News Sources
Kiora Pharmaceuticals Reports Third Quarter 2025 Results; Company Advances Pipeline with Two Actively Enrolling Phase 2 Clinical Trials for Retinal Diseases
07-11-2025
yahoo.com
Kiora Pharmaceuticals Granted U.S. Patent Covering Additional Formulations for the KIO-100 Family of Anti-Inflammatory Compounds
01-12-2025
yahoo.com
Retinal Disease Expert Dr. Taiji Sakamoto Joins Kiora Pharmaceuticals' Scientific Advisory Board
27-01-2026
yahoo.com
Kiora Pharmaceuticals to Present at Oppenheimer's 36th Annual Healthcare Life Sciences Conference
19-02-2026
yahoo.com
Kiora Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Results; Company Advances Retinal Disease Pipeline with Two Active Phase 2 Clinical Trials
25-03-2026
yahoo.com
Kiora Pharmaceuticals Announces Private Placement for Up to $24 Million Led by Perceptive Advisors
07-04-2026
yahoo.com
Plus Therapeutics Appoints Eric J. Daniels, M.D., MBA, as Chief Development Officer to Advance Clinical Pipeline
09-04-2026
yahoo.com
Kiora's Phase 1 ABACUS Study of KIO-301 in Retinitis Pigmentosa Published in Nature Medicine; Phase 2 Trial Underway
14-04-2026
yahoo.com
What is the current price of KIORA PHARMACEUTICALS INC (KPRX:NASDAQ)?
The current price of KIORA PHARMACEUTICALS INC (KPRX:NASDAQ) is $2.79.
KIORA PHARMACEUTICALS INC (KPRX:NASDAQ) absolute price change since previous trading day?
The absolute price change of KIORA PHARMACEUTICALS INC (KPRX:NASDAQ) since the previous trading day is $0.09.
KIORA PHARMACEUTICALS INC (KPRX:NASDAQ) percentage price change since previous trading day?
The percentage price change of KIORA PHARMACEUTICALS INC (KPRX:NASDAQ) since the previous trading day is 3.3333%.
What is the most recent average sentiment score for KIORA PHARMACEUTICALS INC (KPRX:NASDAQ)?
The most recent average sentiment score for KIORA PHARMACEUTICALS INC (KPRX:NASDAQ) is 83 out of 100.
What is the most recent average sentiment for KIORA PHARMACEUTICALS INC (KPRX:NASDAQ)?
The most recent sentiment for KIORA PHARMACEUTICALS INC (KPRX:NASDAQ) is .
SEC-8K** Filing Available For KIORA PHARMACEUTICALS INC (KPRX:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.